Valacyclovir

Annals of Pharmacotherapy

Volumn 31, Issue 2, 1997, Pages 185-191

  Acosta, Edward P ^a,b   Fletcher, Courtney V ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIMETIDINE; FAMCICLOVIR; FIALURIDINE; PENCICLOVIR; PROBENECID; VALACICLOVIR;

CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; FATIGUE; GASTROINTESTINAL SYMPTOM; GENITAL HERPES; HEADACHE; HERPES VIRUS INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0031033623     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100211     Document Type: Review

References (36)

1. Wagstaff AJ, Faulds D, Goa KL. Aciclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:153-205.
2. Burnette T, de Miranda P. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metab Dispos 1994;22:60-4.
3. Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem 1978;253:8721-7.
4. Datta AK, Pagano JS. Phosphorylation of acyclovir in vitro in activated Burkitt somatic cell hybrids. Antimicrob Agents Chemother 1983;24:10-4.
5. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992;358:160-2.
6. Keller PM, Fyfe JA, Beauchamp L, Lubber LM, Furman PA, Schaeffer HJ, et al. Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol 1981;30:3071-7.
7. Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 1980;255:7204-7.
8. Collins P. The spectrum of antiviral activities of acyclovir in vitro and in vivo. J Antimicrob Chemother 1983;12:19-27.
9. Collins P, Ellis MN. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. J Med Virol 1993;1:58-66.
10. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983;12(suppl):29-37.
11. Beauchamp LM, Orr GF, de Miranda P, Burnette T, Krenitsky TA. Amino acid ester prodrugs of acyclovir. Antiviral Chem Chemother 1992;3:157-64.
12. Soul-Lawton J, Seaber E, On N, Wooton R, Rolan P, Posner J, et al. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995;39:2759-64.
13. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
14. Wang LH, Schultz M, Weller S, Smiley ML, Blum MR. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Antimicrob Agents Chemother 1996;40:80-5.
15. Jacobson MA, Gallant J, Wang LH, Coakley D, Weller S, Gary D, et al. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 1994;38:1534-40.
16. Package insert. Valtrex (valacyclovir hydrochloride), Research Triangle Park, NC: Glaxo Wellcome, Inc., December, 1995.
17. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-53.
18. The International Valacyclovir Study Group, Smiley LM. The efficacy and safety of valacyclovir for the treatment of herpes zoster (abstract). In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, October 17-20, 1993:340.
19. Rockley P, Trying S, Smiley M, and The International Valacyclovir HSV Study Group. Valacyclovir is equally safe and effective for the treatment of recurrent genital herpes virus infections as is acyclovir but with a more convenient dosing (abstract). Clin Res 1993;41:778A.
20. Data on file, Glaxo Wellcome Inc., Research Triangle Park, NC.
21. Tilson HH, Engle CR, Andrews EB. Safety of acyclovir: a summary of the first 10 years experience. J Med Virol 1993;(suppl 1):67-73.
22. Maslo C, Peraldi MN, Desenclos JC, Sraer JD, Rosenbaum W. Evidence for the role of cytomegalovirus in thrombotic microangiopathy in HIV-infected patients (abstract). In: Program and Abstracts of the 2nd Nationl Conference on Human Retroviruses, Washington, DC, January 29-February 2, 1995:171.
23. A randomized, double blind trial of valacyclovir hydrochloride (BW 256U87) prophylaxis for opportunistic cytomegalovirus end-organ disease in patients with advanced HIV infection (<100 CD4+ lymphocytes). AIDS Clinical Trials Group 204 Executive Summary, 1995.
24. Byrnes JJ, Moake JL. Thrombotic thrombocytopenia purpura and the haemolytic-uraemic syndrome: evolving concepts of pathogenesis and therapy. Clin Haematol 1986;15:413-42.
25. Rolan PE, Maillot F, On NT, Posner J. The effects of cimetidine and probenecid on the conversion of a valine ester of acyclovir, 256U, to acyclovir and acyclovir renal clearance in healthy volunteers (abstract). Br J Clin Pharmacol 1993;35:533P.
26. Jeffries D, Barton S, Johnson R, Emery V. Issues in herpes management. Antiviral Chem Chemother 1994;5(suppl 1);23-9.
27. Feinberg J, Cooper D, Hurwitz S, and the ACTG 204/Wellcome 123-014 Study Team. Phase III study of valacyclovir (VACV) for cytomegalovirus (CMV) prophylaxis in patients with advanced HIV disease (abstract). In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995:243.
28. Balfour HH Jr, Kelly JM, Suarez CS, Heussner RC, Englund JA, Crane DD, et al. Acyclovir treatment of varicella in otherwise healthy adolescents. J Pediatr 1990;120:627-33.
29. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM Jr, Feldman S, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 1991;325:1539-44.
30. American Academy of Pediatrics Committee on Infectious Diseases. The use of oral acyclovir in otherwise healthy children with varicella. Pediatrics 1993;91:674-6.
31. Vere Hodge RA. Famciclovir and penciclovir: the mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 1993;4:67-84.
32. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-105.
33. Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicellazoster virus. Antimicrob Agents Chemother 1992;36:2747-57.
34. Package insert. Famvir (famciclovir). Philadelphia: SmithKline Beecham, December 1995.
35. 1996 Drug topics red book update. Montvale, NJ: Medical Economics, December, 1996.
36. Degreef H, Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immuncompetent patients. Int J Antimicrob Agents Chemother 1994;4:241-6.